German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
The prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary ce...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2002
|
| _version_ | 1797057245258711040 |
|---|---|
| author | Herrlinger, U Schabet, M Brugger, W Kortmann, R Küker, W Deckert, M Engel, C Schmeck-Lindenau, H Mergenthaler, H Krauseneck, P Benöhr, C Meisner, C Wiestler, O Dichgans, J Kanz, L Bamberg, M Weller, M |
| author_facet | Herrlinger, U Schabet, M Brugger, W Kortmann, R Küker, W Deckert, M Engel, C Schmeck-Lindenau, H Mergenthaler, H Krauseneck, P Benöhr, C Meisner, C Wiestler, O Dichgans, J Kanz, L Bamberg, M Weller, M |
| author_sort | Herrlinger, U |
| collection | OXFORD |
| description | The prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary central nervous system lymphoma. Thirty-seven patients (median age, 60 years) received 179 biweekly courses of 8 g/m2 methotrexate. Response was assessed after 3 and 6 courses. We had planned to enter 105 patients into the trial. Since fewer than the projected 18 of 37 patients achieved a complete response after an intermediate analysis, the trial was closed. In intention-to-treat analysis, 11 of 37 patients (29.7%) achieved complete response, whereas 14 of 37 patients (37.8%) were found to have progressive disease. The median relapse-free survival among complete response patients was 13.7 months. Multivariate logistic regression analysis revealed that corticosteroid application during the first methotrexate course was associated with complete response. The regimen was well tolerated, but, unlike previously reported results, the activity of high-dose methotrexate was only moderate. |
| first_indexed | 2024-03-06T19:33:33Z |
| format | Journal article |
| id | oxford-uuid:1e47c2fc-d9d8-4d00-b2c2-b94648c67096 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:33:33Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:1e47c2fc-d9d8-4d00-b2c2-b94648c670962022-03-26T11:15:26ZGerman Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1e47c2fc-d9d8-4d00-b2c2-b94648c67096EnglishSymplectic Elements at Oxford2002Herrlinger, USchabet, MBrugger, WKortmann, RKüker, WDeckert, MEngel, CSchmeck-Lindenau, HMergenthaler, HKrauseneck, PBenöhr, CMeisner, CWiestler, ODichgans, JKanz, LBamberg, MWeller, MThe prospective multicenter NOA-03 trial, conducted by the Neuro-Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single-agent high-dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary central nervous system lymphoma. Thirty-seven patients (median age, 60 years) received 179 biweekly courses of 8 g/m2 methotrexate. Response was assessed after 3 and 6 courses. We had planned to enter 105 patients into the trial. Since fewer than the projected 18 of 37 patients achieved a complete response after an intermediate analysis, the trial was closed. In intention-to-treat analysis, 11 of 37 patients (29.7%) achieved complete response, whereas 14 of 37 patients (37.8%) were found to have progressive disease. The median relapse-free survival among complete response patients was 13.7 months. Multivariate logistic regression analysis revealed that corticosteroid application during the first methotrexate course was associated with complete response. The regimen was well tolerated, but, unlike previously reported results, the activity of high-dose methotrexate was only moderate. |
| spellingShingle | Herrlinger, U Schabet, M Brugger, W Kortmann, R Küker, W Deckert, M Engel, C Schmeck-Lindenau, H Mergenthaler, H Krauseneck, P Benöhr, C Meisner, C Wiestler, O Dichgans, J Kanz, L Bamberg, M Weller, M German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title | German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title_full | German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title_fullStr | German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title_full_unstemmed | German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title_short | German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. |
| title_sort | german cancer society neuro oncology working group noa 03 multicenter trial of single agent high dose methotrexate for primary central nervous system lymphoma |
| work_keys_str_mv | AT herrlingeru germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT schabetm germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT bruggerw germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT kortmannr germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT kukerw germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT deckertm germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT engelc germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT schmecklindenauh germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT mergenthalerh germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT krauseneckp germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT benohrc germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT meisnerc germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT wiestlero germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT dichgansj germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT kanzl germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT bambergm germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma AT wellerm germancancersocietyneurooncologyworkinggroupnoa03multicentertrialofsingleagenthighdosemethotrexateforprimarycentralnervoussystemlymphoma |